2023-04-22 08:15:00 ET
Biotech companies yet to generate revenue are some of the riskiest growth stocks out there, but if you can invest in one while it's taking off, your portfolio will thank you.
On that note, according to analysts on Wall Street, shares of Lexicon Pharmaceuticals (NASDAQ: LXRX) could rise by over 162% this year -- and they're already up by nearly 40%. And the company hasn't even launched its first medicine yet, though that could soon change if management has its way.
Let's think about whether this stock could be a smart pickup right now.
For further details see:
Should You Buy This Growth Stock Right Now Before It Potentially Doubles?